Shawn Cross, CFO of Pacira BioSciences (PCRX), executed a transaction involving the exercise and immediate sale of 12,941 shares, valued at approximately $326,000. This move, disclosed in an SEC Form 4 filing, reduced Cross’ direct ownership by nearly 11%, leaving him with 105,341 shares. The transaction was structured under a Rule 10b5-1 trading plan, indicating a pre-planned liquidity strategy rather than a reactionary sale.
This insider activity comes at a time when Pacira’s stock has shown volatility, with a recent 12% increase following the company’s first-quarter earnings report, which beat analyst expectations with a 5% year-over-year revenue growth to $177 million. The company is focusing on expanding its product portfolio and has several promising pipeline developments, including a significant study for Zilretta aimed at osteoarthritis pain management.
For investors, Cross’ continued retention of 62.9% of his pre-transaction shares, alongside 150,000 stock options, suggests potential for future liquidity events and aligns with the company’s growth trajectory, making it a stock to watch closely.
Source: fool.com